Advances in the surgical treatment of Parkinson's disease and other movement disorders

被引:1
作者
Gálvez-Jiménez, N
机构
[1] Cleveland Clin Fdn, Dept Neurol, Parkinsons Dis Clin, Ft Lauderdale, FL 33309 USA
[2] Cleveland Clin Fdn, Dept Neurol, Movement Disorders Program, Ft Lauderdale, FL 33309 USA
[3] Univ Miami, Sch Med, Dept Neurol, Coral Gables, FL 33124 USA
关键词
deep cerebral stimulation; movement disorders; pallidotomy; Parkinson's disease;
D O I
10.33588/rn.2902.98503
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective. To present the latest advances in surgery for patients with Parkinson's disease and other movement disorders, emphasizing pallidotomy and deep cerebral stimulation (DCS), thalamic, pallidal and subthalamic, their indications and complications. Development. Advances in neurophysiology and radiology have led to greater understanding of the physiology of the basal ganglia. This has led to the revival of old surgical techniques (pallidotomy) and the clinical application of new variants on these techniques. Pallidotomy is indicated inpatients with advanced Parkinson's disease who are under the age of 65 years and have no psychiatric complications or drug-induced debilitating dyscinesias. In most of these patients the daily dose of levodopa is reduced by approximately 30%. Any complications which occur are transient. The versatility of adjustment of the parameters of deep cerebral stimulation allow them to be adjusted to the patient's needs. Complications include transitory par aesthesia of the side contralateral to the stimulation, transitory tonic contraction of the face and limbs and in some cases dyskinesias which are similar to those induced by drugs. In the United States of America, the Food and Drugs Administration has authorized the use of thalamic DCS for treatment of essential/familial or Parkinsonian tremor of the hands. It is expected that by the end of this year pallidal-DCS will have been approved for the treatment of rigidify, tremor and bradykinesia in Parkinson's disease. Conclusion. Pallidotomy and DCS seem to be safe, useful techniques for the treatment of late complications of Parkinson's disease and possibly other movement disorders also.
引用
收藏
页码:146 / 152
页数:7
相关论文
共 50 条
  • [31] Zebrafish as an Animal Model for Drug Discovery in Parkinson's Disease and Other Movement Disorders: A Systematic Review
    Vaz, Rita L.
    Outeiro, Tiago F.
    Ferreira, Joaquim J.
    FRONTIERS IN NEUROLOGY, 2018, 9
  • [32] SARS-CoV-2 vaccination, Parkinson’s disease, and other movement disorders: case series and short literature review
    Gabriele Imbalzano
    Claudia Ledda
    Carlo Alberto Artusi
    Alberto Romagnolo
    Elisa Montanaro
    Mario Giorgio Rizzone
    Leonardo Lopiano
    Maurizio Zibetti
    Neurological Sciences, 2022, 43 : 5165 - 5168
  • [33] Social cognition in Parkinson's disease and functional movement disorders
    Silveri, Maria Caterina
    Lo Monaco, Maria Rita
    Tondinelli, Alice
    Petracca, Martina
    Zinzi, Paola
    Fragapane, Serena
    Pozzi, Gino
    Pagnini, Francesco
    Bentivoglio, Anna Rita
    Di Tella, Sonia
    NEUROLOGICAL SCIENCES, 2024, 45 (08) : 3775 - 3784
  • [34] A brief history of surgical therapies for Parkinson disease: How science and serendipity contributed to advances in the surgical treatment of Parkinson disease
    Rothstein, Ted L.
    NEUROSURGERY QUARTERLY, 2008, 18 (02) : 121 - 125
  • [35] Advances in the treatment of the motor symptoms of Parkinson's disease
    Turnbull, C.
    Fitzsimmons, P.
    JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 2009, 39 (01) : 29 - 31
  • [36] Advances in hydrogel for diagnosis and treatment for Parkinson's disease
    Zhu, Peining
    Zhao, Zenghui
    Gao, Yufei
    FRONTIERS IN PHARMACOLOGY, 2025, 16
  • [37] Oxidative stress in Parkinson's disease and other neurodegenerative disorders
    Jenner, P
    PATHOLOGIE BIOLOGIE, 1996, 44 (01): : 57 - 64
  • [39] Rest tremor revisited: Parkinson’s disease and other disorders
    Wei Chen
    Franziska Hopfner
    Jos Steffen Becktepe
    Günther Deuschl
    Translational Neurodegeneration, 6
  • [40] Involvement of α-synuclein in Parkinson's disease and other neurodegenerative disorders
    Krüger, R
    Müller, T
    Riess, O
    JOURNAL OF NEURAL TRANSMISSION, 2000, 107 (01) : 31 - 40